Name

CVRx

Legal name

CVRx, Inc.

Website

https://barostim.com

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Heart Failure Neuromodulation Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

akta.pro secondary industries

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL), Cardiac Rehabilitation Programs (HLADAJAJ)

Keywords

• Heart failure neuromodulation
• Implantable pulse generator
• Baroreflex activation therapy
• Cardiac medical devices
• Heart failure treatment

Headquarters

HQ city

Minneapolis

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Technology or R&D, Operations, Others

Revenue model

1. Barostim system hardware sales: Primary revenue from sale of the Barostim NEO2 implantable pulse generator, Carotid Sinus Lead, and Programmer to hospitals and heart failure treatment centers. Recognized as discrete unit sales recognized at implant / shipment.
2. U.S. commercial revenue (geographic mix): U.S. revenue growth highlighted in quarterly results (Q1 2026 grew 22% in the United States); international/EU presence implied via cvrx.eu. Revenue mix is heavily U.S.-weighted with growth in US implanting centers.
3. Reimbursement / patient access support services: CV-Rx Prior Authorization Service (C-PAS) provides case-by-case coding, coverage, eligibility, prior auth, pre/post service appeals support bundled with device adoption; not a separate paid service but supports device sales funnel.

Pricing tiers

Go-to-market motion4 records

Distribution channels6 records

Marketing channels12 records

Core offering

CVRx develops and commercializes the Barostim System, the first FDA-approved neuromodulation therapy indicated for heart failure symptoms. The Barostim System consists of an implantable pulse generator (current-generation Barostim NEO2, IPG model 2104), a Carotid Sinus Lead (model 1036) sutured to the carotid sinus, and a dedicated clinician-facing Programmer. The system delivers Baroreflex Activation Therapy (BAT) — continuous low-level electrical pulses to carotid baroreceptors — to rebalance autonomic nervous system tone in NYHA Class III (and Class II with recent Class III) heart failure patients with LVEF ≤35% despite guideline-directed medical therapy. CVRx also offers C-PAS, a HIPAA-compliant prior authorization and reimbursement support service bundled with the device.

Product overview

CVRx offers a single integrated medical-device platform, the Barostim System, rather than a multi-product SaaS portfolio. The platform architecture combines three named hardware components — the Barostim NEO2 IPG (current-generation implantable pulse generator, with the Barostim NEO and Barostim Legacy IPGs as prior generations), the Carotid Sinus Lead, and the clinician-facing Programmer — which together deliver Baroreflex Activation Therapy (BAT), CVRx's core neuromodulation therapy for heart failure symptoms. Layered on top of this device platform is C-PAS (CVRx Prior Authorization Service), a reimbursement support service that assists healthcare professionals with insurance approval and coding/billing for the Barostim implant procedure. The Barostim System is the first and only FDA-approved neuromodulation technology indicated for heart failure symptoms (NYHA Class III, and Class II with recent Class III history), and the components fit together as follows: the Carotid Sinus Lead is implanted on the carotid sinus and receives stimulation pulses from the Barostim NEO2 IPG; the Programmer is used by clinicians to interrogate and adjust the IPG; and C-PAS provides the commercial/reimbursement workflow that supports patient access to the system.

Differentiator

Problem solved

Functional benefit

Brands

• Barostim: The company's flagship FDA-approved neuromodulation therapy system for heart failure symptoms.
• Barostim NEO2
• Barostim NEO
• BAT (Baroreflex Activation Therapy)

Products and services

• Barostim System The Barostim System is CVRx's flagship neuromodulation therapy platform for the treatment of advanced heart failure symptoms in adults who remain symptomatic (NYHA Class III or Class II with recent Class III history) on guideline-directed medical therapy, with LVEF ≤35%. The system delivers Baroreflex Activation Therapy (BAT) via an implantable pulse generator (current-generation Barostim NEO2 IPG model 2104) and a Carotid Sinus Lead (model 1036) sutured to the carotid sinus, programmed by a clinician-facing Programmer. It is the first and only FDA-approved neuromodulation technology indicated for heart failure symptoms and is sold to U.S. hospitals and heart failure treatment centers.
• Barostim NEO2 IPG (Implantable Pulse Generator) The Barostim NEO2 is the current-generation Implantable Pulse Generator (IPG model 2104) of the Barostim System. It delivers continuous low-level electrical stimulation to carotid baroreceptors through the Carotid Sinus Lead, has an FDA MR Conditional safety label (magnetic switch auto-pauses therapy during MRI), and supports a 5–6 year battery life. It is sold to hospitals and implanting centers as the next-generation commercial IPG of the Barostim System.
• C-PAS (CVRx Prior Authorization Service) C-PAS is CVRx's HIPAA-compliant in-house prior authorization service that supports healthcare professionals through the insurance approval workflow for the Barostim System. C-PAS provides case-by-case coding, coverage verification, eligibility, prior authorization, and pre/post-service appeals support to operationalize reimbursement and enable hospital-level adoption.

Quantifiable outcome

• +60 yards (≈+44 meters) farther in 6-minute hall walk at 12 months (BeAT-HF)
• +7 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Inspire Medical Systems: Small-cap U.S. neuromodulation medtech commercializing an implantable neurostimulation system (for OSA). Highly comparable to CVRx as a single-platform, implantable neuromodulation company selling direct-to-physician with similar reimbursement and prior-authorization dynamics.
• Axonics: Commercial-stage neuromodulation company developing implantable sacral nerve stimulation devices for incontinence. Comparable as a focused, single-therapy implantable neuromodulation business with similar sales-rep-driven adoption model in physician offices.
• Nevro: Neuromodulation company commercializing spinal cord stimulation systems for chronic pain. Comparable as a small-cap implantable neurostim company with similar reimbursement code dependencies and direct-to-physician sales motion.

Emerging players

• Respicardia / ZOLL Medical: Respicardia developed an implantable neuromodulation system (remedē) targeting central sleep apnea, now part of ZOLL. Most directly comparable as a competing implantable neuromodulation therapy in adjacent cardiovascular/pulmonary indications with overlapping cardiology call points.
• Orchestra BioMed: Clinical-stage company developing cardiac neuromodulation therapies (including a renal denervation program for hypertension). Comparable as a developer of device-based neuromodulation targeting cardiovascular indications with overlapping physician specialties.

Broad incumbents

• LivaNova: Global medtech with neuromodulation (VNS for epilepsy/depression) and cardiovascular (heart-lung machines, oxygenators) franchises. Comparable as a larger incumbent with overlapping cardiac surgery/neuromodulation capabilities relevant to Barostim's call points.
• Medtronic: Largest pure-play medtech with deep cardiac device franchises (CRT-Ds, ICDs, heart failure diagnostics like CardioMEMS). Comparable as a broad incumbent whose HF portfolio and CRM sales infrastructure shape the competitive landscape Barostim navigates.
• Abbott: Major cardiovascular device manufacturer with HF (CardioMEMS), CRM, and structural heart franchises. Comparable as the broad incumbent whose former executives now lead CVRx's commercial and medical organizations.
• Boston Scientific: Major cardiovascular medtech with CRM, interventional cardiology, and structural heart businesses. Comparable as a broad incumbent; Board Chair Kevin Ballinger was previously EVP/Global President of Interventional Cardiology at Boston Scientific.
• Edwards Lifesciences: Focused structural heart and critical care medtech incumbent. Comparable as a larger incumbent in advanced cardiovascular therapy with overlapping heart failure specialist relationships and hospital economic buyer dynamics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/cvrx

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds9 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CVRx